Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss

 
• By Alaric DeArment
  
Enanta announced Phase IIb results for zelicapavir in RSV among adults at high risk. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D